Transat

Customized human cellular models:
- Transient/stable inactivation by RNA interference (RNAi)
- Design & validation of small interfering RNA (siRNA)
- Constitutive/inducible over expression
- Optimization of the transfection efficiency
R&D programs to:
- Optimize cell line transfection efficiency
- Develop new plasmids & viral vectors
- Apply RNAi technology to animals

Activity:

- Contract Research
- Research & Development

Product / Technology type(s) covered:

- Bio
- FP (finished products)
- Technology

Therapeutic targets:

- Cancer

Markets Covered

a. HeadQuarter: France

b. Continent(s) active: Europe

c. Countries active: France

Corporate data:

Number of Employees: 6

Turnover:

Amount:	Year:	Currency:
-	2002	Euro

Year founded: 2002